LEVETIRACETAM HIKMA 100 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
Active substance(s): LEVETIRACETAM
Levetiracetam Hikma 100 mg/ml
concentrate for solution for infusion
Read all of this leaflet carefully before you start using this medicine because it
contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.
• If you get any side effects talk to your doctor or nurse. This includes any possible side
effects not listed in this leaflet.
What is in this leaflet:
1. What Levetiracetam Hikma is and what it is used for
2. What you need to know before you are given Levetiracetam Hikma
3. How Levetiracetam Hikma is given
4. Possible side effects
5. How to store Levetiracetam Hikma
6. Contents of the pack and other information
1. WHAT LEVETIRACETAM HIKMA IS AND WHAT IT IS USED FOR
Levetiracetam Hikma concentrate is an antiepileptic medicine (a medicine used to treat
seizures in epilepsy).
Levetiracetam Hikma is used:
• on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy,
to treat partial onset seizures with or without secondary generalization;
• as an add-on to other antiepileptic medicines to treat:
– partial onset seizures with or without generalisation in adults, adolescents and children
from 4 years of age,
– myoclonic seizures in adults and adolescents from 12 years of age with juvenile
– primary generalised tonic-clonic seizures in adults and adolescents from 12 years of
age with idiopathic generalised epilepsy.
Levetiracetam Hikma concentrate is an alternative for patients when administration of the
antiepileptic oral levetiracetam medicine is temporarily not feasible.
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN LEVETIRACETAM
Do not use Levetiracetam Hikma:
• If you are allergic (hypersensitive) to levetiracetam or any of the other ingredients of this
medicine (listed in Section 6).
Warnings and Precautions
Talk to your doctor before you are given Levetiracetam Hikma:
you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if
your dose should be adjusted.
• If you notice any slowdown in the growth or unexpected puberty development of your child,
please contact your doctor.
• If you notice an increase in seizure severity (e.g. increased number), please contact your
• A small number of people being treated with anti-epileptics such as Levetiracetam
Hikma have had thoughts of harming or killing themselves. If you have any symptoms of
depression and/or suicidal ideation, please contact your doctor.
Other medicines and Levetiracetam Hikma
Please tell your doctor or nurse if you are taking or have recently taken any other medicines,
including medicines obtained without a prescription.
Levetiracetam Hikma with food, drink and alcohol
You may take Levetiracetam Hikma with or without food. As a safety precaution, do not use
Levetiracetam Hikma with alcohol.
Pregnancy and breast-feeding
Ask your doctor or nurse for advice before taking any medicine.
If you are pregnant or if you think you may be pregnant, please inform your doctor.
Levetiracetam Hikma should not be used during pregnancy unless clearly necessary. A risk
of birth defects for your unborn child cannot be completely excluded. Levetiracetam Hikma
has shown unwanted reproductive effects in animal studies at dose levels higher than you
would need to control your seizures.
Breast-feeding is not recommended during treatment.
Driving and using machines
Levetiracetam Hikma may impair your ability to drive or operate any tools or machinery,
as Levetiracetam Hikma may make you feel sleepy. This is more likely at the beginning of
treatment or after an increase in the dose. You should not drive or use machines until it is
established that your ability to perform such activities is not affected.
Levetiracetam Hikma contains sodium
One maximum single dose of Levetiracetam Hikma concentrate contains 2.5 mmol (or
57 mg) of sodium (0.8 mmol (or 19 mg) of sodium per vial). This should be taken into
consideration if you are on a controlled sodium diet.
3. HOW LEVETIRACETAM HIKMA IS GIVEN
A doctor or a nurse will administer you Levetiracetam Hikma as an intravenous infusion.
Levetiracetam Hikma must be administered twice a day, once in the morning and once in the
evening, at about the same time each day.
The intravenous formulation is an alternative to your oral administration. You can switch from
the film-coated tablets or from the oral solution to the intravenous formulation or reverse
directly without dose adaptation. Your total daily dose and frequency of administration remain
Dose in adults and adolescents (from 16 years of age):
General dose: between 1000 mg and 3,000 mg each day.
When you will first start taking Levetiracetam Hikma, your doctor will prescribe you a lower
dose during 2 weeks before giving you the lowest general dose.
Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:
General dose: between 1,000 mg and 3,000 mg each day.
Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing
less than 50 kg: General dose: between 20 mg per kg bodyweight and 60 mg per kg
bodyweight each day.
Method and route of administration:
Levetiracetam Hikma will be diluted in at least 100 ml of a compatible diluent and infused
Levetiracetam 100 mg/ml concentrate for solution for infusion
The following information is intended for medical or healthcare professionals only:
Direction for the proper use of Levetiracetam Hikma is provided in section 3.
One vial of Levetiracetam Hikma concentrate contains 500 mg levetiracetam (5 ml
concentrate of 100 mg/ml). See Table 1 for the recommended preparation and
administration of Levetiracetam Hikma concentrate to achieve a total daily dose of 500 mg,
1000 mg, 2000 mg, or 3000 mg in two divided doses.
Table 1 - Preparation and administration of Levetiracetam Hikma concentrate
Withdrawal Volume of Infusion
Frequency of Total Daily
(half 5 ml vial) 100 ml 15 minutes Twice daily
(one 5 ml vial) 100 ml 15 minutes Twice daily 1000 mg/day
(two 5 ml vials) 100 ml 15 minutes Twice daily 2000 mg/day
mg (three 5 ml vials) 100 ml
This medicinal product is for single use only; any unused solution should be discarded.
For doctors and nurses, more detailed direction for the proper use of Levetiracetam Hikma is
provided in section 6.
Duration of treatment:
• Levetiracetam Hikma is used as a chronic treatment. You should continue Levetiracetam
Hikma treatment for as long as your doctor has told you.
• Do not stop your treatment without your doctor’s advice as this could increase your
seizures. Should your doctor decide to stop your Levetiracetam Hikma treatment, he/she
will instruct you about the gradual withdrawal of Levetiracetam Hikma.
• There is no experience with administration of intravenous levetiracetam for a longer period
than 4 days.
If you stop using Levetiracetam Hikma
If stopping treatment, as with other antiepileptic medicines, Levetiracetam Hikma should be
discontinued gradually to avoid an increase of seizures.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some of the side effects like sleepiness, tiredness and dizziness may be more common at
the beginning of the treatment or at dose increase. These effects should however decrease
Very common (may affect more than 1 user in 10):
• somnolence (sleepiness), headache.
Common (may affect 1 to 10 users in 100):
• anorexia (loss of appetite);
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),
lethargy, tremor (involuntary trembling);
• vertigo (sensation of rotation);
• abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
• asthenia/fatigue (tiredness).
Uncommon (may affect 1 to 10 users in 1000):
• decreased number of blood platelets, decreased number of white blood cells;
• weight decrease, weight increase;
• suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination,
anger, confusion, panic attack, emotional instability/mood swings, agitation;
• amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/
ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention
(loss of concentration);
• diplopia (double vision), vision blurred;
• liver function test abnormal;
• hair loss, eczema, pruritus;
• muscle weakness, myalgia (muscle pain);
Rare (may affect 1 to 10 users in 10,000):
• decreased number of all blood cell types;
• severe hypersensitivity reactions (DRESS);
• decreased blood sodium concentration;
• suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking,
unable to concentrate);
• uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling
movements, hyperkinesia (hyperactivity);
• hepatic failure, hepatitis;
• skin rash, which may form blisters and looks like small targets (central dark spots
surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a
widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes
and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in
more than 30% of the body surface (toxic epidermal necrolysis).
Reporting of side effects
If you get any side effects talk to your doctor or nurse. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more
information on the safety of this medicine.
5. HOW TO STORE LEVETIRACETAM HIKMA
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial and carton box after
EXP. The expiry date refers to the last day of the month.
This medicine does not require any special storage conditions
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Levetiracetam Hikma contains
• The active substance is levetiracetam.
Each ml of solution for infusion contains 100 mg of levetiracetam.
• The other ingredients are: sodium acetate, glacial acetic acid, sodium chloride, water for
What Levetiracetam Hikma looks like and contents of the pack
Levetiracetam Hikma concentrate for solution for infusion is a clear, colourless, sterile liquid.
Levetiracetam Hikma concentrate 5 ml vial is packed in a cardboard box of 10 vials.
Marketing Authorisation Holder and Manufacturer
Hikma Farmacêutica (Portugal), S.A.
Estrada do Rio da Mó nº8, 8A, 8B - Fervença, 2705-906 Terrugem SNT, Portugal
Consilient Health (UK) Ltd.
No. 1 Church Road, Richmond upon Thames, Surrey, TW9 2QE
This medicinal product is authorised in the Member States of the EEA under the
Austria: Levetiracetam Hikma 100 mg/ml, Konzentrat zur Herstellung einer Infusionslösung
Germany: Levetiracetam Hikma 100 mg/ml, Konzentrat zur Herstellung einer Infusionslösung
Levetiracetam Hikma, 100 mg/ml, Concentrato per soluzione per infusione
Portugal: Levetiracetam Hikma 100 mg/ml, Concentrado para solução para perfusão
This leaflet was last revised in May 2016
In use shelf life: from a microbiological point of view, the product should be used immediately
after dilution. If not used immediately, in-use storage time and conditions prior to use are the
responsibility of the user and would normally not be longer than 24 hours at room
temperature (15º - 25ºC), unless dilution has taken place in controlled and validated aseptic
Levetiracetam Hikma concentrate was found to be physically compatible and chemically
stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at
controlled room temperature 15-25°C.
• Sodium chloride (0.9%) injection
• Lactated Ringer’s injection
• Dextrose 5% injection
Source: Medicines and Healthcare Products Regulatory Agency